Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting

#8722 Contiguous Overlapping Peptide allergy immunotherapeutic AllerT confirms sustained efficacy in the second year following treatment
Teile den Beitrag mit Freunden

Recent Posts

Kommentar verfassen

Schadensersatzanspruch für Wirecard Anleger
Scroll Up